Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas taps proteostasis in potential $1.2bn alliance

This article was originally published in Scrip

Executive Summary

Assuming all milestones are met and options exercised, a new deal with Japan's Astellas will provide a bonanza for Proteostasis, being worth potentially more than $1.2bn to the privately-held US drug discovery venture.

You may also be interested in...



Bumpy Japan Zolgensma Review Holds Lessons For Applicants

Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise

Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.

Topics

Related Companies

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel